Navigation Links
D-Pharm Secures Funding From Israel's Chief Scientist's Office
Date:4/6/2008

REHOVOT, Israel, April 7 /PRNewswire/ -- D-Pharm announced today that it received notice from Israel's Chief Scientist's Office (CSO) of its commitment to match expenditures on four of D-Pharm's R&D programs with a total grant of up to NIS 11 million (over $3 million).

Alex Kozak, PhD, CEO and President of D-Pharm, said "We are grateful to the CSO for this vote of confidence and its firm support over the years, from the time of the company's inception as a technological incubator. The CSO's backing has helped us to build a robust pipeline with two advanced clinical stage products in stroke (DP-b99) and epilepsy and migraine (DP-VPA) followed by an exciting range of preclinical developments in Alzheimer's disease, cancer and psoriasis".

D-Pharm's drug-development programs emerged from the company's unique platform technology of lipid-like medicine. The CSO grant supports four major company developments: GMP production of DP-b99 in-house, IND preparations and initiation of a pivotal Phase III trial in stroke patients; a Phase II migraine study of DP-VPA in Israeli medical centers; and two preclinical programs, DP-460 for Alzheimer's disease and LipidoMimetix for cancer.

The Chief Scientist's Office has supported D-Pharm since its establishment, providing grants of about $18 million, excluding this latest announcement.

About D-Pharm Ltd.

D-Pharm (http://www.dpharm.com) is clinical stage biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm's pipeline includes advanced clinical stage products DP-b99 for treatment of acute ischemic stroke patients and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and prophylaxis of migraine. D-Pharm recently received Israeli health ministry approval to commence a Phase II study of DP-VPA in migraine patients. DP-460 is i
'/>"/>

SOURCE D-Pharm Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
2. Aerovance Secures $20 Million in Debt Financing
3. Amarin Secures Global Intellectual Property Rights for Lipid Programs
4. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
5. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
6. Taligen Therapeutics Secures Series B Financing
7. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
8. Dendreon Secures $130 Million Committed Equity Financing Facility
9. Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing.
10. Altheus Therapeutics Secures $3.6 Million in Venture Capital
11. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
(Date:8/20/2014)... Fla. , Aug. 20, 2014 ... will host a conference call to provide an ... 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. ... 9126599 Live web cast: www.neurotropebioscience.com , under "Investor ... hours after completion through September 2, 2014 at ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/19/2014)... 20, 2014 One of the ... is an inadequate vascular supply. Nutrient and gas ... tissues is critical for successful regeneration and integration ... mitigate deficiencies in vascularization and promote angiogenesis in ... optimizing scaffold design and architecture, and enhancing scaffolds ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... N.J., Oct. 4 In conjunction with,its third quarter 2007 ... 24), Covance Inc. (NYSE: CVD ) is pleased to ... will be broadcast,live over the Internet on Thursday, October 25 ... Quarter 2007 Earnings Webcast and Slide Presentation When: ...
... Inc.,(NYSE: SMA ), an independent provider of ... medical markets, announced today that the Audit,Committee of ... review of,apparent irregularities with respect to the Company,s ... unit. The review follows a,report by management earlier ...
... today announced that Solomon Steiner, Chairman and CEO of Biodel,will ... San,Francisco, CA on October 11th at 11:00 AM PT. ... webcast of the,presentation in the investor relations section of Biodel,s ... be available for,14 days. About Biodel Inc. Biodel ...
Cached Biology Technology:Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement 2Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement 3Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007 2
(Date:8/21/2014)... smog-producing toxins in past decade, GTA still violates ... that while the Greater Toronto Area (GTA) has ... to smog, the city continues to violate the ... can cause or aggravate health problems such as ... a set of complex photochemical reactions involving volatile ...
(Date:8/21/2014)... 2014 Nxt-ID, Inc. (OTCQB: NXTD), a biometric ... announced today that its shares of common stock and ... in its proposed underwritten public offering of common stock ... Nasdaq Capital Market, subject to closing of its proposed ... and will trade under the symbol "NXTD" and "NXTDW," ...
(Date:8/21/2014)... are the ultimate source of all organic matter that ... algae, too, to suck up climate-warming carbon dioxide from ... the ocean. Now, by using a combination of satellite ... viruses infecting those algae are driving the life-and-death dynamics ... essentially the same, and this has important implications for ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Viruses take down massive algal blooms, with big implications for climate 2
... Boston, MA - Tiny particles only billionths of a meter ... human haircould offer big hope in a small package to the ... everything from jewelry to coins and cell phones, say scientists at ... issue of Nature Nanotechnology, the team will report a ...
... the largest study of its kind, researchers from a consortium ... linked to late-onset Alzheimer,s disease. Each of these genes adds ... the disease, and together they offer a portal into the ... to determine who is at risk of developing the disease, ...
... Medicine researchers are part of a consortium that has identified ... a person developing Alzheimer,s disease later in life. The ... The consortium also contributed to the identification of a ... United States and Europe. "Mount Sinai has unique resources ...
Cached Biology News:Nanoparticles offer hope for common skin allergy 2Nanoparticles offer hope for common skin allergy 3Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 2Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 34 new genes identified for Alzheimer's disease risk 2
Bovine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11:...
...
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 13(S)-HODE ... by incubation of linoleic acid with plant and ... the adhesion of tumor cells to the endothelium ...
...
Biology Products: